Pasi A. Jänne
帕西·扬内
MD, PhD
Director, Lowe Center for Thoracic Oncology; Professor of Medicine, Harvard Medical School胸部肿瘤学罗氏中心主任；哈佛医学院医学教授
👥Biography 个人简介
Dr. Pasi Jänne is a renowned thoracic oncologist at Dana-Farber known globally for EGFR-targeted therapy. He has also been a principal investigator in the DeLLphi-301 trial of tarlatamab, a DLL3-targeting BiTE antibody showing breakthrough activity in relapsed SCLC.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Tarlatamab / DLL3 BiTE in SCLC
Led the DeLLphi-301 phase II trial of tarlatamab in relapsed SCLC, resulting in FDA accelerated approval and establishing a new class of bispecific immunotherapy for this disease.
Representative Works 代表性著作
Tarlatamab for small-cell lung cancer after at least two lines of therapy (DeLLphi-301)
New England Journal of Medicine (2023)
Phase II trial demonstrating durable responses with the DLL3xCD3 BiTE tarlatamab, leading to FDA accelerated approval in relapsed SCLC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 帕西·扬内 的研究动态
Follow Pasi A. Jänne's research updates
留下邮箱，当我们发布与 Pasi A. Jänne（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment